Its role in injury recovery remains a focus of ongoing research (1)
The REDEFINE1 Phase 3 trial showed 22.7% weight loss over 68 weeks in adults with obesity/overweight (no T2DM), exceeding the 20.2% seen with tirzepatide in SURMOUNT5
Lancet Neurol 15(5):455532 Reisberg B et al (2003) Memantine in moderate-to-severe Alzheimers disease
We believe these data underscore the potential of CagriSema to address unmet medical needs in obesity and support long-term disease management." The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomized, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 ) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomized, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 )
Injectable B12 is typically given when someone has a confirmed deficiency, which may be due to: Pernicious anaemia Low stomach acid or long-term use of acid-blocking medications Gastrointestinal disorders like IBD or coeliac disease But I need you to know, a B12 deficiency is a serious issue
